Navigation Links
FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia
Date:5/6/2009

CONFERENCE CALL

The company has scheduled a conference call for tomorrow, Thursday, May 7, 2009 at 10:30 AM ET. During the call, Mihael H. Polymeropoulos, M.D., President and CEO and Stephanie R. Irish, Acting Chief Financial Officer, will discuss the FDA's approval of Fanapt(TM). Investors can call 1-866-314-4865 (domestic) and 1-617-213-8050 (international) prior to the 10:30 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos. A replay of the call will be available Thursday, May 7, 2009, at 1:30 PM ET and will be accessible until Thursday, May 14, 2009, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 55054292.

The conference call will be broadcast simultaneously on the company's Web site, http://www.vandapharma.com. Investors should click on the Investor Relations tab and are advised to go to the Web site at least 15 minutes early to register, download, and install any necessary software. The call will also be archived on the Vanda Web site for a period of 30 days, through June 6, 2009.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda Pharmaceuticals Inc. is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to dif
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
2. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
3. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
4. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
5. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
6. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
7. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
8. FDA Approves First Hepatitis B Viral Load Test
9. U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinsons Disease
10. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
11. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... DIEGO, Jan. 22, 2015  ResMed Inc. (NYSE: RMD ... 2014. Revenue for the quarter was $423.0 million, a 10 ... (a 14 percent increase on a constant currency basis). Net ... to the quarter ended December 31, 2013. Diluted earnings per ...
(Date:1/22/2015)... Jan. 22, 2015  Profil Institute for Clinical Research, Inc., ... obesity, announced today a new textbook,  Translational Research Methods ... Springer, a leading global scientific publisher. The ... techniques for use in early phase clinical studies of ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ... Market by Allergen Source, Product & by End User - ... The global allergy diagnostics market is valued at ... a CAGR of 12.67%, to reach $2,230.72 million by 2019. ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... SAN DIEGO, Nov. 9, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ... September 30, 2009. , Arena reported a lower net loss allocable ... million, or $0.38 per share, compared to a net loss allocable ... million, or $0.76 per share, and a net loss allocable to ...
... Mass., Nov. 9 Groundbreaking articles in current issues ... for the first time explore, in depth, the emergence ... and its potential benefits for patients. , In these ... who is a member of the prestigious Medical Scientist ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9Medicinal Use of Marijuana: Past, Present and Future...A Fresh Look by Experts in the Field 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 IsoComforter, Inc. has ... machine with patented IsoTube design to treat specific body parts ... the most progressive and easy to use patented cold therapy ... and sports related orthopedic and muscle injuries. IsoComforter has ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
(Date:1/22/2015)... As interest in the value of spiritual support ... Rev. Eric J. Hall , president and CEO of ... be the keynote speaker on January 27 at an international ... , The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual ...
(Date:1/22/2015)... a new blog post presenting a list of vehicles that cannot ... Some types of vehicles cannot be covered under an ordinary auto ... see if their vehicle qualifies for auto insurance coverage. , ... that cannot be covered by a plan. Clients have little options ...
(Date:1/22/2015)... Step into a macabre world where plants hold ... Wicked Plants, the Museum’s latest featured exhibition, opens Saturday, ... and diabolical plants inside of a dilapidated, Victorian home. ... physical and neurological processes between botanicals and the human ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... Dec. 17 CareFusion Corporation (NYSE: CFN ) announced ... by TRC Capital Corporation (TRC) to purchase up to four million ... shares of common stock outstanding. TRC,s offer price of $23.50 per ... common stock on Dec. 14, 2009, the last full trading day ...
... , , HOUSTON, Dec. ... a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin Board: ... commercialization of its microarray-based OvaDx(TM) Pre-Symptomatic Ovarian ... development - the rights to which have been assigned ...
... LONDON, December 17 Researchers from the ... in the UK are today,encouraging families worldwide to take ... that shows two-thirds of people,across the globe are not walking ... likely (71%) and Austrians (63%) most likely to,walk together. , ...
... New ... family caregiver , ... (PRWEB) December 17, 2009 -- The National Alliance on Mental Illness (NAMI) praises a new ... nearly one-in-three American adults who serve as a family caregiver. , , ,The study is ...
... ... has driven these changes , ... Charlotte, N.C. (Vocus) December 17, 2009 -- Morehead, the human capital research firm, will host ... hour-long webinar will be broadcast on Wednesday, January 27, 2010 at 1:00 p.m. EST. ...
... ... like Google Local and in front of their local customers by establishing a simple ... Webtyde Internet Marketing. , ... New Orleans, LA (PRWEB) December 17, 2009 -- In order to be competitive ...
Cached Medicine News:Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 2Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 3Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 4Health News:The Family Walk - a Dying Tradition Around the World? 2Health News:NAMI Applauds New Report on Caregiving 2Health News:NAMI Applauds New Report on Caregiving 3Health News:Morehead Presents Webinar on "The State of Employee Engagement: A Year in Review" 2Health News:New Orleans Based Internet Marketing Is Helping Small Businesses Get a Chance to Shine On the Web 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: